^
Association details:
| Biomarker: | FOLH1 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | lutetium zadavotide guraxetan (PNT2002) (Ionizing radiation emitter, PSMA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
Published date:
04/24/2023
Excerpt:
Lantheus Holdings...and POINT Biopharma Global...announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer (mCRPC). Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet medical needs. PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope no-carrier-added 177Lu.
